Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Jun 2022
Novartis announces FDA approval of Beovu for the treatment of diabetic macular oedema
1 June 2022 - Approval is based on year one data from the Phase III KESTREL and KITE clinical trials investigating ...
Posted by Michael Wonder on 01 Jun 2022
EMA appoints Chief Medical Officer
1 June 2022 - Steffen Thirstrup has been appointed as Chief Medical Officer of the EMA. ...
Posted by Michael Wonder on 01 Jun 2022
NICE recommends potentially life-changing treatment for people with short bowel syndrome
1 June 2022 - A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged ...
Posted by Michael Wonder on 01 Jun 2022
Filgotinib maleate for patients with moderate to severe active ulcerative colitis
1 June 2022 - NICE has published evidence based recommendations on the use of filgotinib maleate (Jyseleca) for the treatment ...
Posted by Michael Wonder on 01 Jun 2022
FDA grants efanesoctocog alfa breakthrough therapy designation for haemophilia A
1 June 2022 - Designation is based on XTEND-1 Phase 3 study data demonstrating a clinically meaningful prevention of bleeds and ...
Posted by Michael Wonder on 01 Jun 2022
Government response to independent PHARMAC review
1 June 2022 - The Government has released its response to the recommendations of the final report of the independent ...
Posted by Michael Wonder on 31 May 2022
argenx announces the UK MHRA has granted early access to efgartigimod for generalised myasthenia gravis
31 May 2022 - Efgartigimod was granted a promising innovative medicine designation by UK’s MHRA in November 2021. ...
Posted by Michael Wonder on 31 May 2022
Swiss drug prices still soar above European levels
31 May 2022 - Compared with nine other European countries, Switzerland remains a high-price island for medicines, according to an annual ...
Posted by Michael Wonder on 31 May 2022
Schedule of Pharmaceutical Benefits - 1 June 2022
1 June 2022 - The June 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 May 2022
Y-mAbs Announces FDA acceptance of biologics license application for Omblastys (omburtamab) for the treatment of neuroblastoma for priority review
31 May 2022 - Y-mAbs Therapeutics today announced that the biologics license application for Omblasyts (omburtamab) for the treatment of paediatric ...
Posted by Michael Wonder on 31 May 2022
Priothera receives fast track designation for mocravimod in combination with allogeneic haematopoietic stem cell transplant for post remission therapy of acute myeloid leukaemia patients
31 May 2022 - Priothera today announces that the U.S. FDA has granted fast track designation for mocravimod in combination with ...
Posted by Michael Wonder on 31 May 2022
New Zealand Pharmaceutical Schedule - 1 June 2022
1 June 2022 - The June 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 May 2022
Timber Pharmaceuticals receives FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis
31 May 2022 - Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial. ...
Posted by Michael Wonder on 31 May 2022
TG Therapeutics announces FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS
31 May 2022 - New PDUFA goal date of 28 December 2022. ...
Posted by Michael Wonder on 31 May 2022
US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027 for the as needed treatment or prevention of symptoms in asthma patients
31 May 2022 - Results from Phase 3 trials conducted by Avillion in over 4,000 patients show that PT027, a novel ...